Related references
Note: Only part of the references are listed.Preventive effect of tertiary lymphoid structures on lymph node metastasis of lung adenocarcinoma
Sho Wakasu et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2023)
Granzyme B for predicting the durable clinical benefit of anti-PD-1/PD-L1 immunotherapy in patients with non-small cell lung cancer
Jae Heun Chung et al.
TRANSLATIONAL CANCER RESEARCH (2022)
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial
Mary O'Brien et al.
LANCET ONCOLOGY (2022)
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
Enriqueta Felip et al.
LANCET (2021)
Combined Evaluation of Tumor-Infiltrating CD8+and FoxP3+Lymphocytes Provides Accurate Prognosis in Stage IA Lung Adenocarcinoma
Fumihiko Kinoshita et al.
ANNALS OF SURGICAL ONCOLOGY (2020)
Granzyme B is correlated with clinical outcome after PD-1 blockade in patients with stage IV non-small-cell lung cancer
Daan P. Hurkmans et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Granzyme B nanoreporter for early monitoring of tumor response to immunotherapy
Anh Nguyen et al.
SCIENCE ADVANCES (2020)
Prognostic impact of CD8 and programmed death-ligand 1 expression in patients with resectable non-small cell lung cancer
Seok-Hyun Kim et al.
BRITISH JOURNAL OF CANCER (2019)
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
Tony S. K. Mok et al.
LANCET (2019)
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
Howard West et al.
LANCET ONCOLOGY (2019)
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer
M. D. Hellmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater
Martin Reck et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Prognostic value of PD-L1 expression in combination with CD8(+) TILs density in patients with surgically resected non-small cell lung cancer
Hui Yang et al.
CANCER MEDICINE (2018)
IDO1 in cancer: a Gemini of immune checkpoints
Lijie Zhai et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2018)
Indoleamine 2,3-dioxygenase 1 and programmed cell death-ligand 1 co-expression correlates with aggressive features in lung adenocarcinoma
Yuka Kozuma et al.
EUROPEAN JOURNAL OF CANCER (2018)
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
S. J. Antonia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Determination of poor prognostic immune features of tumour microenvironment in non-smoking patients with lung adenocarcinoma
Tomonari Kinoshita et al.
EUROPEAN JOURNAL OF CANCER (2017)
Immunotoxins in cancer therapy: Review and update
Bahman Akbari et al.
INTERNATIONAL REVIEWS OF IMMUNOLOGY (2017)
PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project
Fred R. Hirsch et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Interferon-γ derived from cytotoxic lymphocytes directly enhances their motility and cytotoxicity
Purnima Bhat et al.
CELL DEATH & DISEASE (2017)
Granzyme B PET Imaging as a Predictive Biomarker of Immunotherapy Response
Benjamin M. Larimer et al.
CANCER RESEARCH (2017)
Predictive relevance of PD-L1 expression combined with CD8+TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy
Takaaki Tokito et al.
EUROPEAN JOURNAL OF CANCER (2016)
Clinical Significance of PD-L1 Protein Expression in Surgically Resected Primary Lung Adenocarcinoma
Kazuki Takada et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Prognostic and predictive value of tumor-infiltrating lymphocytes for clinical therapeutic research in patients with non-small cell lung cancer
Dong-Qiang Zeng et al.
ONCOTARGET (2016)
Prognostic Role of Tumor-Infiltrating Lymphocytes in Lung Cancer: a Meta-Analysis
Yiting Geng et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2015)
How Do Cytotoxic Lymphocytes Kill Cancer Cells?
Luis Martinez-Lostao et al.
CLINICAL CANCER RESEARCH (2015)
Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma
Cheng Lin et al.
CLINICAL LUNG CANCER (2015)
Perforin and granzymes: function, dysfunction and human pathology
Ilia Voskoboinik et al.
NATURE REVIEWS IMMUNOLOGY (2015)
Surface markers of lymphocyte activation and markers of cell proliferation
Maria Shipkova et al.
CLINICA CHIMICA ACTA (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Granzymes in cancer and immunity
S. P. Cullen et al.
CELL DEATH AND DIFFERENTIATION (2010)
The IASLC lung cancer staging project: Proposals for the revision of he TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours
Peter Goldstraw et al.
JOURNAL OF THORACIC ONCOLOGY (2007)
CD4(+) T cells in cancer stroma, not CD8(+) T cells in cancer cell nests, are associated with favorable prognosis in human non-small cell lung cancers
O Wakabayashi et al.
CANCER SCIENCE (2003)
Share Paper
